This opportunity funds research aimed at decreasing adverse drug reactions caused by multiple medications, integrating genetic and biomarker data into clinical decision-making, and improving medication management. Projects should leverage advanced health technologies and data analytics to prevent prescription cascades and support updated clinical guidelines, ultimately enhancing patient outcomes and reducing healthcare costs.
Eligible applicants include legal entities from EU and associated countries, with specific provisions allowing US entities to receive funding. Applicants must meet admissibility, financial, and operational capacity conditions as described in the Horizon Europe Work Programme annexes.
